About N4admin

This author has not yet filled in any details.
So far N4admin has created 39 blog entries.

Roundtable: What are the current investment trends in the pharmaceutical industry and how are they influencing the sector’s direction?

2024-06-27T15:08:18+01:00June 27th, 2024|Article, Blog, News|

Pharma’s Almanac’s Q2 2024 roundtable ‘What are the current investment trends in the pharmaceutical industry and how are they influencing the sector’s direction?’ features a response from Nigel Theobald, CEO, N4 Pharma.Contributing to the discussion, Nigel highlights the need for investment into new non-lipid delivery systems like Nuvec® in [...]

Article: Are oral formulations of oligonucleotide therapeutics within reach?

2024-06-18T09:24:23+01:00June 18th, 2024|Article, Blog, News|

Our latest article explores the challenges with targeting the gastrointestinal (GI) tract and outlines the current strategies aiming to unlock the potential of oral delivery for siRNA drugs targeted against GI diseases and cancers. We discuss why silica nanoparticles, such as Nuvec®, are one of the most promising siRNA [...]

Share Spotlight: Biotech firm N4 Pharma is delivering cutting edge solutions to the UK

2024-05-31T09:31:11+01:00May 31st, 2024|Article, Blog, News|

Shares Magazine shines a spotlight on N4 Pharma (N4P:AIM), revolutionising biotech with advanced delivery systems for nucleic acids in oncology, gene therapy, and vaccines. Our patented mesoporous silica nanoparticles and newly acquired lipid-peptide delivery platform ensure precise, targeted treatment. We aim to become a leading supplier to major pharma [...]

News: N4 Pharma announces collaboration with SRI to target and treat cells in the human body that have been previously unreachable

2024-05-14T16:11:18+01:00May 14th, 2024|Blog, News|

Our latest news release for the trade media announces N4 Pharma’s research collaboration agreement with SRI, an independent non-for-profit research institute based in Silicon Valley, California, to combine Nuvec with SRI’s proprietary  FOX Three Molecular Guidance System™ (MGS)  to increase intercellular delivery to specific target cells. On the back of [...]

Interview: N4 Pharma’s CEO Nigel Theobald discusses strategic moves and future of pharma

2024-05-09T09:45:23+01:00May 9th, 2024|Article, Blog, News|

In an interview with World Pharma Today, Nigel Theobald, CEO N4 Pharma, answers questions about the company’s latest news and future plans. Key highlights from the discussion include: Acquisition: our recent acquisition of Nanogenics Limited and how it enhances our product offerings in gene therapy. Collaborative partnerships: our partnerships [...]

Article: A drug delivery strategy emerges that has the potential to transform cancer therapy

2024-03-07T12:06:54+00:00March 7th, 2024|Article, Blog, News|

In our latest article, we look at how the dual delivery of siRNA – via delivery systems such as Nuvec® – holds the potential to pave the way for a new era of improved efficiency in cancer treatment. Nuvec® has the potential to offer a solution that reduces the [...]

Independent appraisal of N4 Pharma’s Nuvec® platform by EpiVax consultant

2024-01-24T09:30:37+00:00January 24th, 2024|News|

N4 Pharma’s Nuvec® platform has been independently appraised by Dr. Amy S. Rosenberg, Senior Director of Immunology and Protein Therapeutics at EpiVax. In the report Dr. Rosenberg assesses how N4 Pharma’s breakthrough Nuvec® platform might address the current shortcomings in cancer therapy. The novel silica nanoparticle delivery system can [...]

Poster presentation: Enhancing adenovirus gene transfer using novel nanoparticles complexes

2023-10-19T15:41:46+01:00October 12th, 2023|Blog, News|

Our research partners at Brunel University London found that adenovirus (Av) – an effective gene delivery vehicle for vaccinations – complexed with Nuvec®, can significantly improve adenovirus transduction. In the study, researchers investigated the effect of using Nuvec to improve Av gene transfer. To identify the optimal concentration [...]

Acquisition of Nanogenics Ltd

2024-02-20T16:22:26+00:00September 29th, 2023|Blog, N4 Pharma Investor Presentations, News|

N4 Pharma is pleased to announce the acquisition of a controlling interest, through a subscription for new ordinary shares, in Nanogenics Limited, a company with a complementary lipid and peptide-based delivery system called LipTide®, which it is using to develop a novel siRNA product targeting an unmet clinical need in [...]

Go to Top